Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer

PARSOL 1789 CONGRESSIONAL SUPPORT

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

PARSOL 1789 CONGRESSIONAL SUPPORT includes recent letters to FDA Commissioner David Kessler from Sens. Frank Lautenberg (D-NJ) and Bill Bradley (D-NJ) and Reps. Herb Klein (D-NJ), Roy Rowland (D-GA), Don Johnson (D-GA) and Nathan Deal (D-GA). The letters stress the potential public health risk that may be created by many sunscreen's lack of UVA protection and urge FDA to address the status of Givaudan-Roure's broad-spectrum UVA filer Parsol 1789 (avobenzone) as part of the OTC sunscreen rulemaking

Table

View full table

Topics

Tags:
Consumer
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

RS000156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By